Evidence map›Paper›PMID 41755553›Full record

ArticleBioanalysis2026

A fully automated novel solid-phase extraction method for siRNA drug extraction and quantitation across multiple tissues using LC-MS.

Tony Karlsborn, Carl L Stenbratt, Amalyn Nain-Perez, Mikko Hölttä

Abstract read
In one paragraph

Article in Bioanalysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tony KarlsbornDrug Metabolism and Pharmacokinetics & Biomarker Bioanalysis, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Carl L StenbrattDrug Metabolism and Pharmacokinetics, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Amalyn Nain-PerezOligonucleotide Chemistry and Targeted Delivery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Mikko HölttäDrug Metabolism and Pharmacokinetics & Biomarker Bioanalysis, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApproaches such as liquid-liquid extraction and two-step liquid-liquid extraction combined with SPE has been widely used for extraction of oligonucleotide therapeutics. It has been more challenging to develop a generic one-step SPE method that can be used across multiple tissue types. MATERIALS &

methodsAn SPE method was developed for extraction of oligonucleotide therapeutics from tissue homogenates utilizing an ASO internal standard and a siRNA analyte. The method was fully automated using a liquid handler and an automated SPE station. Quantification of the siRNA antisense was performed using LC-MS, with calibration samples prepared in a surrogate matrix.

resultsThe fully automated SPE method enabled quantification of the siRNA antisense across nine different tissues from three different species. The SPE method utilizing surrogate matrix calibration was compared to liquid-liquid extraction by analyzing in-vivo samples using both workflows, showing good agreement between the two different extraction methods.

conclusionsThis manuscript presents a one-step SPE method greatly reducing blank tissue requirements and sample preparation workload by enabling use of surrogate matrix calibration and full automation. The presented SPE method simplifies and reduces analytical time in bioanalysis of tissue biodistribution studies and adheres to the principles of 3R.

Indexed as

Liquid Chromatography-Mass SpectrometryRNA, Small InterferingSolid Phase ExtractionAnimalsAutomationCalibrationChromatography, LiquidHumansLiquid-Liquid ExtractionMiceTandem Mass SpectrometryTissue DistributionRNA, Small InterferingautomationLC-MS/MS analysisoligonucleotide therapeuticssiRNA quantificationSolid phase extraction (SPE)surrogate matrix calibrationtissue homogenates

Identifiers

PMID41755553
PMCPMC12998004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.